



Cross-border Healthcare Intervention Trials in Ireland Network

PAIGE2 – Pragmatic Lifestyle Pregnancy and Post Pregnancy Intervention for Overweight Women with Gestational Diabetes Mellitus.







<u>Overview</u>

- What is GDM why is it important?
- The PAIGE study what they did
 - what worked
 - what did they find out
 - what next
- The PAIGE2 study
- PAIGE2 & CHITIN
- PAIGE2 & MLB











What is GDM?

Gestational diabetes mellitus (GDM) is defined as glucose intolerance with onset or first recognition during pregnancy

GDM develops during pregnancy, like other types of diabetes, it affects how your cells use sugar, which can lead to high blood sugar, this in turn can affect pregnancy outcomes for mother and infant.

It's not fully understood why some women develop gestational diabetes, however alterations in glucose metabolism are a normal physiological adaptation that occurs during pregnancy.

During pregnancy, the placenta, which connects the fetus to the maternal blood supply, produces high levels of hormones.

As the baby grows, the placenta produces more and more insulin-counteracting hormones.










Diagnosing GDM

GDM is diagnosed by administering a 2-hour 75a g oral glucose tolerance test (OGTT).



Board



Screening – occurs between 24 and 28 weeks of gestation











<u>Risks</u>

- Large for gestational age birthweight/macrosomia
- Need for assisted delivery (Caesarean Section)
- 50% more likely to develop GDM in future pregnancy
- High risk of developing type 2 diabetes in the future
- Childhood and adult obesity in offspring









Prevention

Eat healthy foods. Choose foods high in fibre and low in fat and calories. Focus on fruits, vegetables and whole grains.

Keep active. Exercising before and during pregnancy can help protect from developing gestational diabetes. Aim for 30 minutes of moderate activity on most days of the week. Take a brisk daily walk. Cycle. Swim.

Lose excess pounds before pregnancy. Weight loss during pregnancy is not recommended. But for women planning to get pregnant, losing extra weight beforehand may help reduce the risk of developing GDM









PAIGE

Background - GDM is associated with a 7-fold ↑ risk of type 2 diabetes

High gestational weight gain and postpartum weight retention are established predictors of long-term obesity.

<u>Aim</u> - To determine the impact of a postnatal lifestyle intervention program for overweight women with previous gestational diabetes mellitus (PAIGE).









<u>Methods</u>

- Women with a BMI >25 & previous GDM were recruited at 6 weeks postpartum to participate in a multicenter randomized controlled trial
- The intervention comprised of a 1-hour educational program, a free 3-month referral to a commercial weight management organization (Slimming World), a pedometer, and structured telephone and text support, in addition to usual care.
- The control group received standard care only. The primary outcome was weight loss at 6 months.









<u>Results</u>

Sixty women were randomized (29 intervention; 31 control) in two centers.

The intervention group demonstrated significant weight loss at 6 months after randomization compared with the control group: mean \pm SD, 3.9 \pm 6 7.0 kg vs 0.7 \pm 3.8 kg (*P* = 0.02).

With respect to well-being measures, bodily pain was significantly reduced in the intervention group (P = 0.007).









Results

Characteristic	Intervention (n = 29)	Control (n = 31)		
Age, y	34.2 (4.3)	33.2 (5.3)		
Weight, kg	89.6 (16.8)	90.2 (16.4)		
BMI, kg/m ²	34.1 (6.3)	33.6 (5.4)		
Waist circumference, cm	103.7 (11.2)	105.8 (12.1)		
Hip circumference, an	116.8 (12.9)	116.2 (11.4)		
Fat mass, kg	39.7 (12.8)	39.1 (11.9)		
Fat free mass, kg	49.9 (5.7)	51.2 (6.5)		
White ethnicity, n (%)	25 (86.0)	26 (84.0)		
Employed, n (%)	22 (76.0)	20 (65.0)		
Education, y	17.1 (3.0)	16.3 (3.1)		
Married/cohabiting, n (%)	24 (83.0)	27 (87.0)		
Smoker, n (%)	3 (10.0)	4 (13.0)		
Parity, mean number of pregnancies	2.5 (1.2)	2.3 (1.2)		
Primiparous, n (%)	5 (17.0)	8 (26.0)		
Breastfeeding, n (%)	7 (24.0)	14 (45.0)		
Diet-only treatment of GDM in most recent pregnancy, n (%)	8 (28.0)	9 (29.0)		
Time since delivery, wk ^a	9.8 (3.2)	9.3 (2.2)		
Fasting plasma glucose, mmol/L	5.05 (0.56)	5.15 (0.66)		
2-h plasma glucose after OGTT, mmol/L	6.09 (1.76)	6.14 (2.28)		
Fasting serum insulin, mU/L ^b	11.7 (6.3-19.1)	12.6 (7.7-13.9)		
2-h serum insulin, mU/L ^c	41.1 (18.2-56.4)	33.3 (16.9-46.4)		
HbA1c, mmol/mol) ^d	35.0 (4.2)	37.4 (4.1)		
LDL cholesterol, mmol/L ^e	3.0 (0.7)	3.4 (0.9)		
HDL cholesterol, mmol/L ^f	1.5 (0.4)	1.5 (0.3)		
Cholesterol, mmol/L ^f	5.3 (0.8)	5.6 (1.1)		
Triglycerides, mmol/L ^f	1.4 (0.9-2.1)	1.3 (0.7-1.6)		

Table 1 Paraline Characteristics of Study Participants (N = 60)

Data are mean (SD), median (interquartile range), or n (%).



Northern Ireland - Ireland - Scotland





Downloaded from https://academic.oup.com/jcem/article-abstract/103/7/2478/4

Results

Table 2. Group Differences in Anthropometric and Blood Glucose Measurements From Baseline to 6 Months After Intervention

Variable	Intervention (n = 20)			Control (n = 25)			Intervention Effect ^a	
	Baseline	6 Mo After Intervention	Change	Baseline	6 Mo After Intervention	Change	Estimate (95% CI)	P Value (Two- Tailed)
Weight, kg ^b	91.6 (17.3)	87.7 (17.8)	-3.9 (7.0)	90.6 (16.4)	91.2 (17.8)	0.7(3.9)	-4.5 (-8.1 to -0.9)	0.02
BMI, kg/m ^{2c}	34.8 (6.7)	33.4 (6.9)	-1.4(2.7)	33.5 (5.6)	33.8 (6.2)	0.2 (1.4)	-1.6 (-3.0 to -0.2)	0.03
Waist circumference, cm ^d	106.2 (10.1)	103.3 (12.0)	-2.9 (6.7)	106.8 (13.3)	108.4 (12.4)	1.7 (5.3)	-4.5 (-8.4 to -0.7)	0.02
Hip circumference, cm ^d	117.9 (13.8)	115.8 (14.4)	-2.1 (6.3)	115.9 (11.0)	114.9 (10.6)	-1.0 (4.5)	-1.2 (-4.7 to 2.4)	0.51
Fat mass, kg d	41.0 (12.8)	38.4 (14.5)	-2.6(7.5)	37.9 (11.5)	38.0 (12.7)	0.1 (5.7)	-2.7 (-6.9 to 1.6)	0.22
Fat free mass, kgd	51.5 (4.9)	50.4 (6.9)	-1.0(6.1)	51.7 (6.9)	51.9 (6.4)	0.1 (5.4)	-1.2 (-4.8 to 2.5)	0.52
Fasting plasma glucose, mmoVL ^e	5.1 (0.5)	5.3 (0.9)	0.2 (0.5)	5.0 (0.4)	5.1 (0.5)	0.1 (0.4)	0.1 (-0.2 to 0.4)	0.49
2-h plasma glucose after OGTT, mmol/L ^f	5.9 (1.8)	6.3 (2.5)	0.4 (1.8)	5.7 (1.4)	5.6 (0.9)	-0.1 (0.9)	0.5 (-0.4 to 1.4)	0.27
Fasting serum insulin, mU/L ^g	14.9 (8.1)	15.5 (7.5)	0.6 (4.8)	10.1 (4.1)	14.5 (8.1)	4.4 (7.0)	-1.8 (-6.3 to 2.7)	0.43

Data are mean (SD).







Results

Table 3. Results From the SF-12v2™ Health Survey Questionnaire and the Exercise Self-Efficacy Questionnaire at 6 Months in the Intervention and Control Groups

Variable	Intervention (n = 20)			Control (n = 25)			Intervention Effect ^a	
	Baseline	6 Mo After Intervention	Change	Baseline	6 Mo After Intervention	Change	Estimate (95% CI)	P Value (Two-Tailed)
SF-12v2™ Health			100 3155			100		
Survey								
General health ^b	51.6 (20.1)	46.1 (21.8)	-5.5(25.3)	57.5 (23.3)	55.2 (24.6)	-2.3(22.3)	-6.3 (-19.5 to 7.0)	0.35
Mental health ^c	56.9 (18.8)	55.0 (10.3)	-1.9(16.4)	60.7 (10.9)	57.1 (12.4)	-3.8 (13.8)	-0.9 (-7.6 to 5.8)	0.79
Physical	85.0 (22.1)	94.1 (10.2)	9.1 (18.9)	86.4 (21.4)	79.3 (23.0)	-7.0 (22.6)	15.3 (5.1 to 25.5)	0.004
functioning	W 8	20 - 20	40 M	8 2	8 8	16 16	MI 00 MI	()
Bodily pain ^e	55.4 (31.3)	5.4 (10.6)	-50.0 (31.0)	57.7 (27.7)	36.5 (37.7)	-21.2 (38.0)	-30.6 (-51.9 to -9.3)	0.007
Vitality	45.8 (23.1)	50.0 (21.0)	4.2 (32.4)	51.1 (17.6)	52.2 (21.2)	1.1 (26.6)	-2.2 (-15.9 to 11.6)	0.75
Role emotional ⁹	84.2 (19.9)	82.2 (22.9)	-2.0 (23.7)	85.3 (21.5)	88.0 (21.1)	2.7 (21.3)	-5.3 (-17.7 to 7.2)	0.40
Social functioning ^g	86.8 (22.6)	81.6 (27.4)	-5.3 (28.5)	82.6 (23.2)	81.5 (28.4)	-1.1 (33.3)	-1.3 (-18.5 to 15.9)	0.88
Role physical ^h	71.7 (23.5)	85.5 (15.7)	13.8 (26.6)	78.0 (25.3)	82.5 (25.5)	4.5 (28.6)	4.6 (-8.5 to 17.8)	0.48
Exercise	10 10	N 50				N 2	14 CT	
self-efficacy								
Sticking to ith	3.4 (0.8)	3.4 (0.8)	-0.1 (0.6)	3.3 (0.6)	2.9 (0.8)	-0.4(0.8)	0.4 (0.0-0.8)	0.07
Making time to exercise ^h	3.7 (0.7)	3.5 (0.7)	-0.3 (0.9)	3.6 (0.7)	3.3 (0.8)	-0.3 (0.9)	0.1 (-0.3 to 0.6)	0.52

Data are mean (SD).





What worked?

- Education session and accompanying booklet
- Structured text and phone support
- CMWO for those who registered

What didn't?

- Timing of recruitment
- Pedometer
- Lack of family support










PAIGE2 – Pragmatic Lifestyle Pregnancy and Post Pregnancy Intervention for Overweight Women with Gestational Diabetes Mellitus.

















- Sligo University Hospital
- Letterkenny University Hospital
- Antrim Area Hospital
- Ulster Hospital
- Royal Victoria Hospital
- Our Lady of Lourdes Hospital, Drogheda,











Making Life Better 2012–2023 is the ten-year public health strategic framework. The framework provides direction for policies and actions to improve the health and wellbeing of people in Northern Ireland.

'Achieving a healthier Northern Ireland will hinge on what we do together, through policy and practice, to influence the key factors which impact on life chances and choices and ultimately on health and wellbeing'







Thank you to all our collaborators

Dr Brid Farrell, Assistant Director of Service Development, PHA

- Dr. Adele Kennedy, Consultant Diabetologist, Antrim Area Hospital
- Dr. Ciara Mulligan, Consultant Endocrinologist, Ulster Hospital
- Dr. Tomas Ahern, Consultant Endocrinologist and Physician, Our Lady of Lourdes Hospital, Drogheda
- Professor Cathy McHugh, Consultant Endocrinologist, Sligo University Hospital

Professor Fidelma Dunne, Consultant Endocrinologist, Letterkenny


University Hospital













Cross-border Healthcare Intervention Trials in Ireland Network

Thank you





